Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders

Roche has secured approval from the US Food and Drug Administration (FDA) for its Rituxan (rituximab), in combination with glucocorticoids, to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients two years of age and older.